BioTuesdays

Category - Markets

Reshape-Lifesciences-Logo
Markets

AGP starts ReShape Lifesciences at buy; PT $12

Alliance Global Partners initiated coverage of ReShape Lifesciences (OTCQB:RSLS) with a “buy” rating and price target of $12. The stock was quoted at $7.54 in afternoon trading on Feb. 18. ReShape is a rare pure-play in...

February 18, 2021
Titan Pharmaceuticals Logo
Markets

Maxim ups Titan Pharma to buy from hold; PT $11

Maxim Group upgraded Titan Pharmaceuticals (NASDAQ:TTNP) to “buy” from “hold” with a new price target of $11, citing multiple strategy, management, cap-structure and financing changes at Titan, which should position the...

February 18, 2021
Hepion Pharmaceuticals
Markets

Hepion Pharma closes $88.4-million offering

Hepion Pharmaceuticals (NASDAQ:HEPA) closed a public offering of 44.2 million common shares at a price of $2 each for gross proceeds of $88.4-million. After deducting underwriting fees and other offering expenses, net...

February 18, 2021
Artelo Biosciences Logo
Markets

Maxim ups Artelo Biosciences PT to $5 from $3

Maxim Group raised its price target for Artelo Biosciences (NASDAQ:ARTL) to $5 from $3, citing rising valuations across the cannabinoid and cannabis space, and as Artelo begins to map out its path forward as a cancer...

February 17, 2021
Amryt-Logo
Markets

SVB Leerink starts Amryt Pharma at OP; PT $40

SVB Leerink launched coverage of Amryt Pharma (NASDAQ:AMYT) with an “outperform” rating and $40 price target. The stock closed at $14.15 on Feb. 12. “Filsuvez is poised to be the first approved treatment for...

February 16, 2021
Artelo Biosciences Logo
Markets

Ladenburg starts Artelo Biosciences at buy; PT $7

Ladenburg Thalmann initiated coverage of Artelo Biosciences (NASDAQ:ARTL) with a “buy” rating and price target of $7. The stock closed at $1.63 on Feb. 11. Artelo is developing first-in-class, proprietary therapeutics...

February 12, 2021
Plus Therapeutics Logo
Markets

HCW starts Plus Therapeutics at buy; PT $7

H.C. Wainwright launched coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and $7 price target. The stock closed at $3.75 on Feb. 10. Plus is focused on developing novel therapies against brain cancer. The...

February 11, 2021
Tracon Pharmaceuticals Logo
Markets

Maxim starts TRACON Pharma at buy; PT $24

Maxim Group initiated coverage of TRACON Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $24 price target. The stock closed at $9.91 on Feb. 9. TRACON is developing a differentiated anti-PD-L1 checkpoint...

February 10, 2021
Cycle-Therapeutics-Logo
Markets

Maxim ups Cyclo Therapeutics PT to $25 from $12

Maxim Group more than doubled its price target for Cyclo Therapeutics (NASDAQ:CYTH) to $25 from $12, citing updates from the Phase 1 and Phase 1/2 clinical programs for Trapsol Cyclo (TC) in Neimann-Pick Type C (NPC)...

February 9, 2021